This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME/CE activities may not contain the most up-to-date information available.
Click here to view our current activities in Gastroenterology.
Overview of MCRC
Over the past few years, results have become available from a wide variety of clinical trials utilizing numerous combination regimens of chemotherapy and targeted biologics in the treatment of colorectal cancer. Recent clinical trials and their relevance to clinical practice are discussed in this overview.
Axel Grothey, MD
Case Study: Stage IV Metastatic Colon Cancer in a Patient with Ulcerative Colitis
An elderly man with unresectable metastatic colon cancer responds well to initial treatment with a combination chemotherapy-targeted biologic regimen but experiences debilitating toxicity over time. Current state-of-the-science options for first- and second-/third-line combination chemotherapy/targeted biologic regimens are discussed, as well as management of side effects associated with these treatments.
J. Philip Kuebler, MD, PhD
Case Study: Surgically Resectable Metastatic Colorectal Cancer
The multidisciplinary management of a patient with surgically resectable metastatic colon cancer—including the complications of surgery, timing of biologics, and the role of adjuvant therapy—are all discussed in this presentation.
Cathy Eng, MD
This CME activity is designed for clinicians involved in the treatment of patients with metastatic colorectal cancer.
The goal of this activity is to provide clinicians involved in the treatment of metastatic colorectal cancer patients with state-of-the-science information on current treatment options.
- Evaluate the efficacy and toxicity profiles of combination chemotherapy/targeted biologic regimens to determine the most appropriate first-line and second-/third-line therapy for your individual patients with metastatic colorectal cancer.
- Apply your knowledge of the adverse events associated with available combination chemotherapy/targeted biologic regimens for metastatic colorectal cancer to effectively manage side effects and maintain patients on treatment.
- Integrate knowledge of surgical options, the role of adjuvant chemotherapy, and the timing of targeted biologic regimens to provide optimum multidisciplinary treatment of your patients with metastatic colorectal cancer.
CME INFORMATION: PHYSICIANS
Statement of Accreditation
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Projects In Knowledge designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contract for Mutual Responsibility in CME
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME activity, please see your current Physicians’ Desk Reference (PDR).
Cathy Eng, MD, is on the advisory board of Pfizer Inc.
Axel Grothey, MD, is on the advisory board of Sanofi-Aventis, Roche Pharmaceuticals, Amgen Inc, Genentech Inc, and Bristol-Myers Squibb. Dr. Grothey has disclosed that he will reference unlabeled/unapproved uses of cetuximab, panitumumab, and bevacizumab in his presentation.
J. Philip Kuebler, MD, PhD, is on the speakers bureau of Sanofi-Aventis; and is a member of the advisory board of Genentech Inc and Sanofi-Aventis. Dr. Kuebler has disclosed that he will reference unlabeled/unapproved use of bevacizumab in his presentation.
Peer Reviewer has no significant relationships to disclose.
Projects In Knowledge’s staff members have no significant relationships to disclose.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
This independent CME activity is supported by an educational grant from Bristol-Myers Squibb, ImClone Systems Inc, and Genentech BioOncology.
Requires Flash 8 or higher
and high-speed internet